Akoya Biosciences (AKYA, Financial) has announced a strategic collaboration with the Singapore Translational Cancer Consortium to embark on the STCC Unified PD1/PDL1 Evaluation of Response study. This groundbreaking initiative is set to explore and authenticate critical biomarkers that can predict patient responses to immune checkpoint inhibitors using Akoya's cutting-edge IO60 panel for spatial proteomic analysis.
The study, referred to as the SUPER study, marks a first for Singapore as it focuses on a distinctive pan-cancer cohort consisting of 200 patients. This group includes 100 individuals who are exceptional responders and 100 who experience hyperprogression when treated with immune checkpoint inhibitors. By examining this unique cohort, researchers aim to identify the biological drivers behind the varying treatment outcomes.
Central to this study is the application of Akoya's IO60 panel, combined with other multiomic profiling techniques, to refine biomarker-driven cancer therapies and enhance patient treatment results. The study's primary goals are to determine and confirm the most effective assay combination and biomarker profile for predicting how patients will respond to PD1/PDL1 inhibition.
The collaboration aims to develop a comprehensive assay kit or model that accurately forecasts treatment responses, suitable for clinical use. Additionally, the study seeks to establish a national program for discovering biomarkers among extreme responders—patients showing extraordinary positive or negative treatment responses.
Through this partnership, Akoya's IO60 panel will be instrumental in analyzing tumor microenvironments, shedding light on immune cell interactions and biomarker expression within this pair-matched patient cohort. The insights gained could lead to substantial advancements in cancer immunotherapy strategies and more efficient healthcare cost management.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Akoya Biosciences Inc (AKYA, Financial) is $2.99 with a high estimate of $5.00 and a low estimate of $1.65. The average target implies an upside of 155.56% from the current price of $1.17. More detailed estimate data can be found on the Akoya Biosciences Inc (AKYA) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Akoya Biosciences Inc's (AKYA, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Akoya Biosciences Inc (AKYA, Financial) in one year is $5.22, suggesting a upside of 346.15% from the current price of $1.17. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Akoya Biosciences Inc (AKYA) Summary page.
